AzithromycinMD Home

Category

Antibiotic Stewardship

4 articles

The Hidden Cost of a Z-Pack: What Azithromycin Does to the Gut Microbiome and Why It Matters for Long-Term Patient Outcomes

The Hidden Cost of a Z-Pack: What Azithromycin Does to the Gut Microbiome and Why It Matters for Long-Term Patient Outcomes

Azithromycin's broad-spectrum activity extends well beyond its intended pathogen targets, disrupting the delicate balance of commensal gut bacteria in ways that can persist for weeks to months after a course ends. Clinicians making prescribing decisions must now weigh not only immediate therapeutic benefit but also the downstream consequences of post-treatment dysbiosis. This article synthesizes current evidence on microbiome disruption, secondary infection risk, and recovery trajectories to sup

When Azithromycin Isn't the Answer: A Clinician's Framework for Selecting Macrolide and Non-Macrolide Alternatives

When Azithromycin Isn't the Answer: A Clinician's Framework for Selecting Macrolide and Non-Macrolide Alternatives

Rising resistance rates and evolving patient profiles are forcing prescribers to look beyond azithromycin for common respiratory and sexually transmitted infections. This clinical guide offers structured decision-making pathways and evidence-based substitution strategies tailored to US prescribing contexts. Understanding when—and how—to pivot away from azithromycin is now a core competency in responsible antibiotic stewardship.

Combination Strategies for Community-Acquired Pneumonia: Rethinking Azithromycin's Role in a Resistant Landscape

Combination Strategies for Community-Acquired Pneumonia: Rethinking Azithromycin's Role in a Resistant Landscape

As macrolide resistance continues to reshape the treatment landscape for community-acquired pneumonia, clinicians across the United States are revisiting azithromycin-based combination regimens with fresh scrutiny. Emerging clinical data from hospital systems in multiple US regions suggest that strategic pairing of azithromycin with beta-lactams may still offer meaningful advantages for select patient populations. This article examines the evidence, the pathogens, and the practical decision poin

The Resistance Equation: Why Prescribing Azithromycin for Viral Infections Is Costing US Communities More Than We Realize

The Resistance Equation: Why Prescribing Azithromycin for Viral Infections Is Costing US Communities More Than We Realize

Every unnecessary azithromycin prescription is a small vote for a future where the antibiotic no longer works. Across the United States, azithromycin continues to be prescribed at high rates for respiratory illnesses that are viral in origin, feeding resistance patterns that undermine treatment outcomes for patients who genuinely need the drug. This investigation examines the scope of the problem, the real-world consequences for patients and communities, and what meaningful change actually requi